The Nold Laboratory has its roots in basic science; however, these days one of our a main interests is harnessing our expertise in immunology to explore the molecular mechanisms of several poorly understood and currently largely untreatable diseases of preterm babies, including bronchopulmonary dysplasia (BPD), pulmonary hypertension, intracranial haemorrhage and necrotising enterocolitis. Our primary aim is rapid translation of our findings into clinical medicine, as exemplified by a clinical trial based on one of our discoveries that may establish the first safe and effective treatment for BPD. Our laboratory’s other major focus lies on the new interleukin (IL-)1 family cytokines IL-37 and IL 38. Our revelation of IL-37’s powerful anti-inflammatory properties (Nold..., Nat Immunol 2010) has caused a surge of interest in these previously largely obscure proteins. Examples of current work include identification of IL-37’s cell surface receptor and characterisation of IL-38 in health and disease. Marcel Nold is a clinician-scientist, paediatrician and neonatologist and alumnus Larkins Fellow of Monash University. His work, carried out in Germany, the USA and at the Ritchie Centre / MIMR-PHI Institute in Australia, has received international recognition in the form of numerous awards, including the German Society of Immunology’s Köhler Prize, substantial research funding including from industry partners, and an international patent.